Redutase

Aldose reductase-IN-1 (AT-001, Caficrestat) is a highly potent inhibitor of aldose reductase.Cost-effective and quality-assured.

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).

Imirestat (HOE 843) is an aldose reductase inhibitor that can be used in diabetes research.

Turosteride is a small molecule steroidal 5α-reductase (5α-reductase) inhibitor.Turosteride has antitumor activity for the treatment of oncologic diseases and

Alconil is a biochemical.

Trimethoprim (NSC-106568) inhibits dihydrofolate reductase, CYP2C8, and OCT2 - an antibacterial agent.

MK 0434 is a steroid 5α-reductase inhibitor and hormone antagonist associated with a significant reduction in DHT.

Epalrestat (ONO2235), an aldose reductase inhibitor, helps manage diabetic neuropathy symptoms and slows disease progression.

Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR.

Potent TR inhibitor with IC50: 3.3μM, also inhibits glutathione reductase (IC50: 64.8μM) and T. brucei (EC50: 1μM).

Finasteride (MK-906) is an oral inhibitor of active testosterone 5-alpha-reductase and Ki value is 10 nM.

Fluvastatin sodium (Fluvastatin sodium salt), a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), is a commonly used cholesterol

AKR1Cs-IN-1 (Compound 29) is an effective and broad-spectrum inhibitor of the Aldo-Keto Reductase 1C family (AKR1C1-1C4). It achieves subtype inhibition by simultaneously binding to the SP2 and SP3 pockets, thereby blocking metabolic pathways related to drug resistance. In enzyme assays, AKR1Cs-IN-1 exhibits significant inhibitory activity with IC50 values of 0.09, 0.28, 0.05, and 0.51 µM for AKR1C1, AKR1C2, AKR1C3, and AKR1C4, respectively. The compound shows excellent resensitizing effects in doxorubicin (DOX)-resistant breast cancer cell line MCF-7/ADR, effectively enhancing the cytotoxicity of DOX. AKR1Cs-IN-1 holds promise for research on breast cancer resistance.

ALR2-IN-6 (compound 9) is a potent competitive inhibitor of ALR2, with a Ki value of 0.064 μM. It is applicable in research related to neuropathy, retinopathy, and nephropathy.

DDHF20 is an inhibitor of Staphylococcus aureus, specifically targeting and inhibiting its thioredoxin reductase (TrxR) by acting as a competitive inhibitor at the NADPH binding site. DDHF20 shows potential for research in combating infections related to Staphylococcus aureus.

Isomer-Turosteride, a novel 5α-reductase inhibitor, reduces prostate DHT and has anticancer properties without raising T levels.

ALR2-IN-1: potent, selective inhibitor of ALR2 (IC50=1.42 μM), antiglycemic, antioxidant; for diabetes research.

xnum small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.

3α-Hydroxysteroid Dehydrogenase, Pseudomonas testosteroni (EC 1.1.1.50), is part of the oxidoreductase family. This enzyme utilizes three substrates: androsterone, NAD+, and NADP+, resulting in four products: 5α-androstan-3,17-dione, NADH, NADPH, and H+. It acts on the CH-OH group of donor molecules using NAD+ or NADP+ as an acceptor.

AKR1C2/3-IN-1 (compound 3a) is a potent inhibitor of AKR1C2 and AKR1C3, with IC50 values of 90 nM and 50 nM, respectively. It serves as a radiosensitizer and an enhancer of the cytotoxicity of chemotherapy.

Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.

SPR inhibitor 3 is a small molecule that inhibits the synthesis of BH4.

Ponalrestat is an aldose reductase inhibitor.

Sorbinil is an Aldose reductase inhibitor.

Poliumoside: natural, inhibits glycation (IC50=4.6-25.7 μM) & aldose reductase (IC50=0.85 μM), with antioxidant, antibacterial & hemostatic properties.

Acid Yellow 36 (Metanil Yellow) is an azo dye and a pH indicator. Acid Yellow 36 changes its color from red at pH 1.2 to yellow at pH 2.3.

Methotrexate disodium is an tetrahydrofolate dehydrogenase inhibitor

2-Chloro-1-(4-fluorobenzyl)benzimidazole is an inhibitor of aldose reductase (ALR2).

EBPC is an inhibitor of aldose reductase.

Pralatrexate (10-Propargyl-10-deazaaminopterin) is a folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate

Gonadorelin Acetate (33515-09-2 free base) (Luteinizing Hormone Releasing Hormone (LH-RH)) is hypothalamic neuropeptide which plays a key role in the control of

Sodium aurothiomalate (Miochrysin) inhibits PKC-ι, TrxR; used as an anti-rheumatic and has anti-tumor properties.

AKR1C3-IN-4: potent, selective AKR1C3 inhibitor, IC50 = 0.56 μM, potential for CRPC research.

Alrestatin (AY-22284) is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor.

COH29 is an oral RNR-blocking thiazole that may reduce DNA synthesis and promote apoptosis, with potential cancer-treating properties.

Kopexil is a compound similar to minoxidil that promotes hair growthby inhibiting 5α-reductase and possibly activating potassium channel switches.

Ethaselen (BBSKE) is an oral TrxR inhibitor with IC50 of 0.5 μM (human) and 0.35 μM (rat), targeting a selenocysteine site to fight NSCLC.

Tolrestat (AY-27773) is a potent inhibitor of aldose reductase (IC50 = 35 nM).

Aldose reductase-IN-6 is an AR inhibitor; blocks polyol pathway; reduces sorbitol; diabetic complications research tool.

Zenarestat is an orally active aldose reductase inhibitor capable of ameliorating diabetic peripheral neuropathy in rats with type 2 diabetes.

AY 9944 inhibits DHCR7 enzyme (IC50=13 nM) and sterol isomerase, leading to hypocholesterolemia and 7DHC buildup.

AKR1C3-IN-14 (compound 4) is an inhibitor of AKR1C3 enzyme, exhibiting an IC50 value of 0.122 μM. It reduces excess androgen production by inhibiting the activity of the AKR1C3 enzyme, thereby regulating hormone-mediated signaling. Additionally, AKR1C3-IN-14 plays a role in the biosynthesis of prostaglandin PGF2α, influencing this pathway to regulate cell proliferation. This compound is utilized in the research of prostate cancer.

Risarestat (CT-112) is a potent aldose reductase inhibitor and thyroid hormone receptor (TR) antagonist for the treatment of hypoglycemia.

SN34037, specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor, inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.

Fidarestat (SNK 860),Aldose reductase inhibitor (IC50=26 nM). Targets AKR1B10 (33 μM) and V301L AKR1B10 (1.8 μM). Potential diabetes treatment.

Izonsteride (LY320236) is a selective and potent 5alpha reductase inhibitor with dual action on the type I and type II isoforms of the enzyme.Izonsteride is

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.

Minalrestat(ARI-509) is an orally active and potent aldose reductase inhibitor for the study of impaired microvascular reactivity in diabetic patients.

Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity.